KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Operating Leases (2019 - 2025)

Historic Operating Leases for Pacira BioSciences (PCRX) over the last 7 years, with Q3 2025 value amounting to $48.6 million.

  • Pacira BioSciences' Operating Leases fell 1485.82% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 1485.82%. This contributed to the annual value of $44.6 million for FY2024, which is 1853.99% down from last year.
  • Pacira BioSciences' Operating Leases amounted to $48.6 million in Q3 2025, which was down 1485.82% from $50.9 million recorded in Q2 2025.
  • Pacira BioSciences' Operating Leases' 5-year high stood at $77.7 million during Q1 2022, with a 5-year trough of $44.6 million in Q4 2024.
  • In the last 5 years, Pacira BioSciences' Operating Leases had a median value of $65.7 million in 2023 and averaged $64.3 million.
  • In the last 5 years, Pacira BioSciences' Operating Leases soared by 7023.12% in 2021 and then tumbled by 1853.99% in 2024.
  • Over the past 5 years, Pacira BioSciences' Operating Leases (Quarter) stood at $71.7 million in 2021, then fell by 9.65% to $64.8 million in 2022, then fell by 15.43% to $54.8 million in 2023, then dropped by 18.54% to $44.6 million in 2024, then grew by 8.83% to $48.6 million in 2025.
  • Its Operating Leases was $48.6 million in Q3 2025, compared to $50.9 million in Q2 2025 and $53.1 million in Q1 2025.